Title: Continuing Access to In-Home IVIG Act
Policy area: Health

Summary:
Continuing Access to In-Home IVIG Act
This bill extends the Medicare Intravenous Immune Globulin (IVIG) Demonstration for an additional two years and expands the maximum number of participating beneficiaries from 4,000 to 6,500. The program provides bundled payments for items and services that are necessary for in-home IVIG administration for certain beneficiaries with primary immune deficiency disease.

[Congressional Bills 116th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7839 Introduced in House (IH)]

<DOC>






116th CONGRESS
  2d Session
                                H. R. 7839

   To amend the Medicare IVIG Access and Strengthening Medicare and 
  Repaying Taxpayers Act of 2012 to extend the Medicare Patient IVIG 
                     Access Demonstration Project.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                             July 29, 2020

 Ms. Matsui (for herself and Mr. Brady) introduced the following bill; 
  which was referred to the Committee on Energy and Commerce, and in 
    addition to the Committee on Ways and Means, for a period to be 
subsequently determined by the Speaker, in each case for consideration 
  of such provisions as fall within the jurisdiction of the committee 
                               concerned

_______________________________________________________________________

                                 A BILL


 
   To amend the Medicare IVIG Access and Strengthening Medicare and 
  Repaying Taxpayers Act of 2012 to extend the Medicare Patient IVIG 
                     Access Demonstration Project.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Continuing Access to In-Home IVIG 
Act''.

SEC. 2. EXTENSION OF MEDICARE PATIENT IVIG ACCESS DEMONSTRATION 
              PROJECT.

    (a) Extension of Demonstration Project.--Section 101(b) of the 
Medicare IVIG Access and Strengthening Medicare and Repaying Taxpayers 
Act of 2012 (42 U.S.C. 13951 note) is amended--
            (1) by striking paragraph (1) and inserting the following:
            ``(1) Duration.--Beginning not later than one year after 
        the date of enactment of this Act, the Secretary shall conduct 
        the demonstration project for a period of 3 years and, subject 
        to the availability of funds under subsection (g), the period 
        beginning on October 1, 2017, and ending on December 31, 
        2022.''; and
            (2) in paragraph (2)--
                    (A) by striking ``4,000'' and inserting ``6,500''; 
                and
                    (B) by striking ``2020'' and inserting ``2022''.
    (b) Updated Evaluation and Report.--Section 101(f) is amended--
            (1) by redesignating paragraph (2) as paragraph (3); and
            (2) by inserting after paragraph (1) the following new 
        paragraph:
            ``(2) Updated evaluation and report.--Not later than one 
        year after the date of the enactment of the Continuing Access 
        to In-Home IVIG Act, the Secretary shall submit to Congress an 
        updated report that contains the following:
                    ``(A) The total number of beneficiaries enrolled in 
                the demonstration project during the updated report 
                period.
                    ``(B) The total number of claims submitted for 
                services during the updated report period, 
                disaggregated by month.
                    ``(C) An analysis of the impact of the 
                demonstration on beneficiary access to the in-home 
                administration of intravenous immune globin, including 
                the impact on beneficiary health and well-being.
                    ``(D) An analysis of the impact of in-home 
                administration of intravenous immune globin on overall 
                costs to Medicare, including the cost differential 
                between in-home administration of intravenous immune 
                globin and administration of intravenous immune globin 
                in a healthcare facility.
                    ``(E) A survey of providers and enrolled 
                beneficiaries that participated in the demonstration 
                project that identifies barriers to accessing services, 
                including reimbursement for items and services.
                    ``(F) Recommendations to Congress on the 
                appropriateness of establishing a permanent bundled 
                services payment for the in-home administration of 
                intravenous immune globin for Medicare 
                beneficiaries.''.
    (c) Definition of Updated Report Period.--Section 101(h) is amended 
by adding at the end the following new paragraph:
            ``(4) Updated report period.--The term `updated report 
        period' means the period beginning on October 1, 2014, and 
        ending on September 30, 2020.''.
                                 <all>